The treatment of Parkinson’s disease (PD) requires personalized care, a high degree of polypharmacy, and frequent adjustments to achieve symptom control throughout the disease course…
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic…
TNF-α inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Simponi, and UCB’s Cimzia) are approved to treat nonradiographic axial spondyloarthritis (nr-AxSpA) in Europe and are…
Copy/Paste the key inputs from the product brochure, per guidance from Marketing. The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor…
The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and the long treatment durations. The availability of premium-priced branded agents prescribed…
Migraine, which afflicts approximately 72 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment…
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent…
Non-small-cell lung cancer (NSCLC)—the primary cause of cancer-related mortality in China—has a very dynamic pipeline that includes numerous targeted and biomarker-driven therapies. Notably,…
The negative symptoms of schizophrenia, which often coexist with the positive symptoms, include diminished emotional expression (affective flattening), diminished initiation of goal-directed…
Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management…
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at…
Relapsed / refractory diffuse large B-cell lymphoma (R/R DLBCL) is an aggressive disease with significant unmet need. The treatment landscape has evolved since the approval of various novel…
Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates,omega-3 fatty acid compounds, and PCSK9…